Enhanced Mitochondrial Transient Receptor Potential Channel, Canonical Type 3–Mediated Calcium Handling in the Vasculature From Hypertensive Rats

Bin Wang, PhD; Shiqiang Xiong, PhD; Shaoyang Lin, MS; Weijie Xia, BS; Qiang Li, MD; Zhigang Zhao, MD; Xing Wei, MD; Zongshi Lu, MD; Xiao Wei, MD; Peng Gao, PhD; Daoyan Liu, PhD; Zhiming Zhu, MD

Background—Mitochondrial Ca\(^{2+}\) homeostasis is fundamental to the regulation of mitochondrial reactive oxygen species (ROS) generation and adenosine triphosphate production. Recently, transient receptor potential channel, canonical type 3 (TRPC3), has been shown to localize to the mitochondria and to play a role in maintaining mitochondrial calcium homeostasis. Inhibition of TRPC3 attenuates vascular calcium influx in spontaneously hypertensive rats (SHRs). However, it remains elusive whether mitochondrial TRPC3 participates in hypertension by increasing mitochondrial calcium handling and ROS production.

Methods and Results—In this study we demonstrated increased TRPC3 expression in purified mitochondria in the vasculature from SHRs, which facilitates enhanced mitochondrial calcium uptake and ROS generation compared with Wistar-Kyoto rats. Furthermore, inhibition of TRPC3 by its specific inhibitor, Pyr3, significantly decreased the vascular mitochondrial ROS production and \(\text{H}_2\text{O}_2\) synthesis and increased adenosine triphosphate content. Administration of telmisartan can improve these abnormalities. This beneficial effect was associated with improvement of the mitochondrial respiratory function through recovering the activity of pyruvate dehydrogenase in the vasculature of SHRs. In vivo, chronic administration of telmisartan suppressed TRPC3-mediated excessive mitochondrial ROS generation and vasoconstriction in the vasculature of SHRs. More importantly, TRPC3 knockout mice exhibited significantly ameliorated hypertension through reduction of angiotensin II–induced mitochondrial ROS generation.

Conclusions—Together, we give experimental evidence for a potential mechanism by which enhanced TRPC3 activity at the cytoplasmic and mitochondrial levels contributes to redox signaling and calcium dysregulation in the vasculature from SHRs. Angiotensin II or telmisartan can regulate \([\text{Ca}^{2+}]_{\text{mito}}\), ROS production, and mitochondrial energy metabolism through targeting TRPC3. (J Am Heart Assoc. 2017;6:e005812. DOI: 10.1161/JAHA.117.005812.)

Key Words: mitochondria • pyruvate dehydrogenase • telmisartan • transient receptor potential channel, canonical type 3 • vasoconstriction

Mitochondrial Ca\(^{2+}\) uptake is critical for regulation of numerous cellular processes, including energy metabolism and cytosolic Ca\(^{2+}\) homeostasis.\(^1\) Mitochondria undergo rapid changes in matrix Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_{\text{mito}}\) on cell stimulation to affect the aerobic metabolism,\(^2,\,\,3\) and mitochondrial matrix Ca\(^{2+}\) overload impairs mitochondrial function and leads to reactive oxygen species (ROS) generation.\(^4,\,\,5\) Mitochondrial adenosine triphosphate (ATP) and ROS production can directly affect the vascular function,\(^6\) whereas insufficient ATP supply and excessive ROS production contribute to the pathogenesis of hypertension.\(^7,\,\,8\) Mitochondrial ROS and Ca\(^{2+}\) homeostasis have mutual interplay roles,\(^2\) especially in the vasculature.\(^9\) A group of nonselective cation channels, transient receptor potential channels (TRPCs), have been demonstrated to function in regulating vascular calcium signaling.\(^10\,\,12\)

Our previous study indicated that increased transient receptor potential channel, canonical 3 (TRPC3) was associated with enhanced cytosolic calcium influx and vasoconstriction in the vasculature from spontaneously hypertensive rats (SHRs) compared with Wistar-Kyoto (WKY) rats.\(^13\) Recently, TRPC3 channel protein has been shown to localize in the inner...
Enhanced Mitochondrial TRPC3 in Hypertension  

Wang et al

DOI: 10.1161/JAHA.117.005812

Clinical Perspective

What Is New?

- This study is the first to demonstrate that enhanced mitochondrial transient receptor potential channel, canonical 3 (TRPC3) expression in the vasculature from spontaneously hypertensive rats facilitates mitochondrial calcium entry and reactive oxygen species generation and impairs adenosine triphosphate synthesis.
- TRPC3 gene knockout ameliorates hypertension through reduction of angiotensin II–induced mitochondrial calcium overload and reactive oxygen species generation.
- Telmisartan administration inhibits TRPC3-mediated excessive mitochondrial reactive oxygen species generation and vasoconstriction in the vasculature of spontaneously hypertensive rats.

What Are the Clinical Implications?

- Telmisartan is widely used clinically as an antihypertensive drug. We demonstrate that angiotensin II and telmisartan may exert angiotensin receptor–independent effects by targeting TRPC3 in the vasculature.
- Telmisartan shows a promising and novel antihypertensive pathway through inhibition of vascular mitochondrial TRPC3-mediated redox signaling and calcium dysregulation.

Methods

Animals and Treatment

Eight-week-old male SHRs and normal control WKY rats were obtained from Charles River Laboratories (Wilmington, MA). The rats were maintained at a controlled temperature (21°C to 23°C) under a 12/12-hour light-dark cycle and with free access to food and water. After a 2-week adaptation period, 30 male SHRs and 30 age-matched WKY rats were randomly divided into normal diet (ND) and ND plus telmisartan (Telmi, 5 mg/kg per day) groups (N=15 per group) and treated for 12 weeks. Every 4 weeks the tail-cuff blood pressure (BP) levels were measured. After 12 weeks of intervention, the rats were surgically implanted with telemetric transmitters to measure the 24-hour ambulatory BP levels. Then, the rats were euthanized, and tissue samples were isolated for further experiments.

Wild-type and Trpc3−/− mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Homozygotes, heterozygotes, and wild-type litters were identified according to previously described methods. Briefly, 10 6-month-old Trpc3−/− mice and 10 6-month-old wild-type litters were surgically implanted with 14-day mini-osmotic pumps (Alzet Company, Cupertino, CA) filled with saline or angiotensin II (Sigma, St. Louis, MO) solutions randomly, each subgroup having 5 mice. The dose of angiotensin II was 0.7 μg/day per kilogram body weight. The tail-cuff BP was measured at baseline, as well as at 7 and 14 days after intervention. After intervention, the 24-hour ambulatory BP was measured, and then these animals were euthanized for other experiments. All of the experimental procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of the Third Military Medical University.

Primary Aortic VSMC Culture and Treatment

The VSMC layer was isolated from aortas of WKY rats and SHRs by removing the intima and adventitia. 11 The tissue blocks were then incubated with Dulbecco Modified Eagle Medium (DMEM; Gibco, Gaithersburg, MD) containing 10% fetal bovine serum (Gibco), streptomycin (100 μg/mL), and penicillin (100 U/mL). Cultured VSMCs were plated and grown at 37°C in a humidified atmosphere of 95% air/5% CO2. Cultured VSMCs were used between passages 2 and 8.

Angiotensin II can regulate [Ca2+]mito and ROS production in the mitochondrial respiratory chain and elevate blood pressure through targeting TRPC3 in the vascular smooth muscle cells (VSMCs) from SHRs. Therefore, we hypothesize that enhanced TRPC3-mediated mitochondrial Ca2+ uptake and ROS production involved elevated blood pressure in the vasculatures from SHRs compared with WKY rats.
MitoTEMPO was purchased from Santa Cruz Biotechnology (Dallas, TX). Telmisartan and Pyr3 were all purchased from Sigma-Aldrich (St. Louis, MO).

Small Interfering RNA and Plasmid Overexpression Experiments

RNA interference and overexpression experiments were conducted as previously described. Briefly, Lipofectamine 3000 was purchased from ThermoFisher Scientific (Waltham, MA), and rat TRPC3-specific small interfering RNA (siRNA) and negative control siRNA were purchased from Genecopoeia (Guangzhou, China). The pcDNA-TRPC3myc overexpression plasmid was kindly provided by Dr Craig Montell (Addgene plasmid 25902).

Tail-Cuff and 24-Hour Ambulatory BP Measurements

The tail-cuff BP measurement was conducted using a Softron BP-2010A as previously described. The 24-hour ambulatory BP measurement was conducted as previously described using surgically implanted telemetric transmitters (Data Sciences International, New Brighton, MN). In rats, the measurements were conducted after the animals had received a normal diet or a normal diet plus telmisartan for 12 weeks, whereas mice were assessed 14 days after the implantation of osmotic pumps. The implant catheter was placed into the abdominal aorta of rats or the descending carotid artery of mice. The animals were allowed to recover from the surgery for at least 7 days, and the 24-hour ambulatory systolic and diastolic BP were then measured by telemetry in conscious, unrestrained animals. We collected data once every minute and used the mean values of 24 hours for the analysis.

Measurement of Vascular Reactivity

The vascular reactivity was measured as previously described. Briefly, after the mice or rats were anesthetized with pentobarbital sodium, the mesenteric vascular bed was removed and placed in cold (4°C) Krebs solution (in mmol/L: 118 NaCl, 25 NaHCO₃, 1.1 D-glucose, 4.7 KCl, 1.2 KH₂PO₄, 1.17 MgSO₄, and 2.5 CaCl₂, set to the pH of 7.4). The first branches of the mesenteric arteries (MAs) (for mice) and second branches of the MAs (for rats) were excised with the connective tissues, such as fat. Subsequently, 2-mm MA segments were mounted on a myograph (Danish Myo Technology, Aarhus, Denmark). After incubation in 95% O₂ and 5% CO₂ at 37°C, the MA segments were stretched to optimum baseline tension (1.8 mN for mouse MAs and 2.5 mN for rat MAs). The arteries were then equilibrated for 60 minutes before precontraction with 60 mmol/L KCl. After several washouts, each ring was treated with different vasoactive substances (phenylephrine, U46619, acetylcholine, or nitroglycerin, all purchased from Sigma-Aldrich) or other substances (Pyr3, MitoTEMPO, etc). Isometric contractions were recorded using a computerized data acquisition system (PowerLab/8SP; AD Instruments Pty Ltd, Castle Hill, Australia).

Evaluation of ROS Levels

The ROS levels were measured using a dihydroethidium (DHE) fluorescent probe for cytosolic ROS detection or MitoSOX Red (ThermoFisher Scientific, Waltham, MA) for mitochondrial ROS detection. DHE and MitoSOX staining and detection were conducted as previously described. The cellular H₂O₂ levels were detected using a Hydrogen Peroxide Assay Kit (Beyotime, Shanghai, China). Tissue sections were frozen in optimal cutting temperature compound and quickly sectioned, and the sections were then stained with DHE or MitoSOX dye according to the manufacturers’ protocols. To quantify the intensity of DHE and MitoSOX fluorescence, the plates were measured using a Fluoroskan Ascent Fluorometer (ThermoFisher, Helsinki, Finland). The ROS concentrations are expressed as a normalized value relative to the fluorescence intensity of the control cells. To visualize the staining, the sections or specimens were placed on an inverted fluorescence microscope (Nikon TE2000, Nikon Corporation, Tokyo, Japan).

ATP Content Measurement

The ATP levels in VSMCs were measured using a firefly luciferase-based ATP assay kit (Beyotime, Shanghai, China) as previously described. Briefly, treated VSMCs were lysed with a specific lysis buffer, followed by centrifugation at 12 000g for 5 minutes at 4°C. Subsequently, 100 μL of each supernatant was mixed with 100 μL of an ATP detection solution that had been diluted to the proper working concentration. Luminescence was measured using a Varioskan Flash instrument (ThermoFisher Scientific, Waltham, MA). The protein concentration of each treated group was also measured using a Bradford Protein Assay. The total ATP levels are expressed as nanomoles per milligram protein, and the ratios between different groups were calculated and presented.

High-Resolution Respirometry

Mitochondrial respiratory function was analyzed using a 2-channel titration injection respirometer (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria) equipped with 2 chambers, as previously described. In general, VSMCs were harvested, resuspended in the MiRO5 solution, and transferred separately to oxygraph chambers at a final cell density of ≈1×10⁵ cells/mL. Routine respiration was assessed while respiration was stabilized. The plasma membrane was then...
permeabilized with digitonin (10 μg per 10^6 cells), and Complex I-dependent oxidative phosphorylation (CI_OXPHOS) was measured after addition of glutamate (G, 5 mmol/L), malate (M, 2 mmol/L), and ADP (D, 5 mmol/L). The integrity of the outer mitochondrial membrane was assessed by adding cytochrome c (10 μmol/L). Subsequently, succinate (S, 10 mmol/L) was added to induce maximal oxidative phosphorylation (OXPHOS) capacity with convergent input through CI+II_OXPHOS. After uncoupling with 2-[[4-(trifluoromethoxy) phenyl]hydrazinylidene]propanedinitrile (FCCP; injected step-wise up to 1-1.5 μmol/L) in the noncoupled state, CI+II-supported noncoupled respiration (CI+IIETS) was measured. The addition of rotenone (0.5 μmol/L) allowed the determination of CIETS. Residual oxygen consumption was evaluated after the inhibition of CIII with antimycin A (2.5 μmol/L). CIETS was measured by adding the CIV substrates ascorbate (A, 0.5 mmol/L) and TMPD (N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride) (0.5 mmol/L).

**Respiratory Chain Enzyme Activity Assay**

The respiratory chain enzyme activities were measured as previously described using a Mitochondrial Complexes Activity Assay Kit (Millipore, Darmstadt, Germany) according to the manufacturer’s instructions. The enzyme activities of mitochondrial Complex I were detected at 450 nm and 37°C for 30 minutes, whereas Complex II activities were detected at 600 nm and 37°C for 60 minutes.

**Western Blot and Immunofluorescence**

Western blot and immunofluorescence assays were conducted as previously described. The primary antibody against TRPC3 was purchased from Alomone (Alomone Labs, Jerusalem, Israel), and the primary antibody against GAPDH was purchased from Santa Cruz Biotechnology (Dallas, TX). The primary antibody against phosphorylated PDHE1α (p-PDHE1α) was purchased from Merck-Millipore (Darmstadt, Germany). Primary antibodies against PDHE1α and voltage-dependent anion-selective channel and fluorescently labeled secondary antibodies were purchased from Abcam (Cambridge, MA). Horseradish peroxidase (HRP)-labeled secondary antibodies were purchased from Zhongshan Company (Beijing, China).

**Isolation of Mitochondria From VSMCs and Aortic Tissues**

Mitochondria were isolated from aortic tissues or primary cultured VSMCs using Percoll density gradient centrifugation. Briefly, tissues or cells were homogenized in homogenization buffers (in mmol/L: 225 mannitol, 75 sucrose, 0.1 EGTA and 30 Tris-HCl, pH 7.4) and centrifuged twice at 600g for 5 minutes at 4°C to remove intact cells and nuclei. The supernatant (cytosol fraction) was centrifuged twice (7000g, 10 minutes, 4°C), and the insoluble part was the crude mitochondrial fraction. To obtain the crude mitochondrial fraction, the pellet was resuspended in starting buffer (in mmol/L: 225 mannitol, 75 sucrose and 30 Tris-HCl, pH 7.4) and centrifuged twice at 7000g and 4°C for 10 minutes. Then, crude mitochondrial fraction pellet was resuspended in 2 mL of mitochondria-resuspending buffer (in mmol/L: 250 mannitol, 5 HEPES and 0.5 EGTA, pH 7.4) and loaded on Percoll medium (in mmol/L: 225 mannitol, 25 HEPES, 1 EGTA and 30% Percoll [vol/vol], pH 7.4). After centrifugation (95 000g, 30 minutes, 4°C), the mitochondrial fraction was isolated. Pure mitochondria were then obtained by centrifuging twice at 6300g for 10 minutes. The protein pellets were solubilized in SDS sample buffer and analyzed by Western blotting using antibodies against TRPC3, voltage-dependent anion-selective channel protein (as a mitochondrial control) and GAPDH (as a loading control).

**Intracellular and Mitochondrial Calcium Measurement**

The cytosolic and mitochondrial Ca^{2+} concentrations, [Ca^{2+}]_{c} and [Ca^{2+}]_{mito}, were measured using Fura-2 AM and Rhod-2 AM (ThermoFisher Scientific, Waltham, MA), respectively. For the [Ca^{2+}]_{c} measurement, cells were digested and resuspended in Hank’s Balanced Salt Solution (in mmol/L: 136 NaCl, 5.4 KCl, 0.44 KH2PO4, 0.34 Na2HPO4, 5.6 d-glucose, 10 HEPES and 1 CaCl2, pH 7.4). For loading with Fura-2, the cells were incubated with 1 μmol/L Fura-2 AM and 0.025% F-127 (from Sigma-Aldrich) for 30 minutes at 37°C in the dark, washed 3 times with Ca^{2+}-free Hank’s Balanced Salt Solution and resuspended in Ca^{2+}-free Hank’s Balanced Salt Solution. Fluorescence was measured at baseline and after treatment at an emission of 510 nm using excitation wavelengths of 340 and 380 nm. The resultant data are presented as Fx/F0, where Fx is the ratio of fluorescence between excitation at 340 and 380 nm with emission at 510 nm, and F0 is the mean F340 nm/F380 nm value during the pretreatment period in each experiment. Changes in [Ca^{2+}]_{c} were deduced from the ratios of the transient increases in the fluorescence intensity at 340 and 380 nm.

For the [Ca^{2+}]_{mito} measurement, cells were digested and resuspended using an extracellular solution (in mmol/L: 120 NaCl, 6 KCl, 0.3 CaCl2, 2 MgCl2, 12 d-glucose, 12 sucrose, and 10 HEPES-free acid, pH 7.4). For loading with Rhod-2, cells were incubated with 5 μmol/L Rhod-2 AM and 0.025% F-127 for 30 minutes at 37°C in the dark and washed 3 times with an extracellular solution. Cells were permeabilized with 10 μmol/L digitonin for 5 minutes at 37°C in the intracellular solution (in mmol/L: 120 KCl, 10 NaCl, 1 KH2PO4, 20 HEPES,
2 Mg-ATP, 2 succinate and proteinase inhibitor mixtures, pH 7.2) and then washed 3 times with intracellular solution. Agonists (ATP or histamine) and Ca²⁺ were added to the washing solution for treatment. The fluorescence was measured at an emission wavelength of 581 nm and an excitation wavelength of 552 nm at baseline and after treatment. The statistical analysis of the calcium measurements is graphically presented as the \( RX/R_0 \) value, where \( R \) is the emission values induced by excitation and \( R_0 \) is the mean value of \( R \) during the pretreatment period in each experiment.

**Statistical Analysis**

The data are presented as the mean±SEM. For the comparisons of means between 2 groups, unpaired Student t test was used to examine the differences. For the comparisons of means among 3 or more groups, ANOVA followed by Bonferroni post hoc tests were used to examine the differences. For the analysis of wire myograph data, concentration-response curves were analyzed with a nonlinear regression followed by a 1-way ANOVA method to compare the \( E_{\text{max}} \) as the maximal response and \( pD_2 \) as the negative logarithm of the drug concentration that produced 50% of \( E_{\text{max}} \) among these groups. For the analysis of tail-cuff systolic BP changes in rats and angiotensin II–infused mice with repeated tests over time, a repeated-measures ANOVA method was used to compare the blood pressure changes over time. Meanwhile, for other comparisons with nonrepeated tests in animal experiments and all of the cellular experiments, unpaired Student t tests or 1-way ANOVA were used to examine differences between or among these groups. All the data analysis was conducted using GraphPad Prism (La Jolla, CA) or SPSS 19.0 (IBM Analytics, Armonk, NY). Two-sided \( P \)-value less than 0.05 was considered as statistically significant.

**Results**

**Increased Mitochondrial TRPC3 Expression in the Vasculature From SHRs**

First, we examined the expression levels of mitochondrial TRPC3 using purified mitochondria from primary cultured VSMCs from

---

**Figure 1.** The whole-cell and mitochondrial TRPC3 expression levels in primary VSMCs from WKY rats and SHRs. A, TRPC3 immunoreactivity was detected by the anti-TRPC3 antibody (96 kDa) in homogenates of primary VSMCs from SHRs. B and C, The TRPC3 expression levels in cell lysates and purified mitochondria of primarily cultured VSMCs were analyzed by Western blotting, using VDAC protein as a mitochondrial control and GAPDH as an internal reference in (B). D indicates DMSO treatment. Three Western blot bands were quantified and analyzed in the lower panels (C). *\( P < 0.05 \), **\( P < 0.01 \). SHR indicates spontaneously hypertensive rats; Telmi, telmisartan; TRPC3, transient receptor potential channel, canonical type 3; VDAC, voltage-dependent anion-selective channel; VSMC, vascular smooth muscle cells; WKY, Wistar-Kyoto.
WKY rats and SHRs. It showed that the expression levels of total and mitochondrial TRPC3 were significantly increased in VSMCs from SHRs compared with WKY rats but were significantly decreased on telmisartan treatment (Figure 1). These results indicated that increased vascular mitochondrial TRPC3 expression in SHRs was inhibited by telmisartan.

Enhanced Mitochondrial TRPC3-Mediated Calcium Handling in the Vasculature From SHRs

To assess the function of increased mitochondrial TRPC3 expression in the vasculature of SHRs, we examined the \([\text{Ca}^{2+}]_{\text{mito}}\) changes in VSMCs. Specifically, ATP or histamine
significantly increased the [Ca^{2+}]_{mito} in VSMCs from SHRs compared with WKY rats, whereas the administration of telmisartan or TRPC3 inhibitor (Pyr3) significantly attenuated this effect (Figure 2A through 2D). Moreover, we used permeabilized VSMCs to exclude the contribution of plasma membrane TRPC3 to [Ca^{2+}]_{mito}. The [Ca^{2+}]_{mito} remained higher in SHRs, and this increase was significantly reduced by pretreatment with telmisartan or Pyr3 (Figure 2E and 2F). Furthermore, TRPC3 knockdown with a specific siRNA significantly reduced the [Ca^{2+}]_{mito} in the permeabilized VSMCs from SHRs (Figure 2G and 2H), whereas the overexpression of TRPC3 with the pcDNA-TRPC3 plasmid significantly augmented the [Ca^{2+}]_{mito} in WKY (Figure 2I and 2J). Taken together, these results suggest that increased mitochondrial TRPC3 expression regulated mitochondrial Ca^{2+} homeostasis in the vasculature of SHRs.

We further confirmed that increased mitochondrial TRPC3-mediated calcium uptake affected vascular tone. Specifically, mitoTEMPO or telmisartan treatment inhibited increases in store-operated calcium entry in the VSMCs of SHRs (Figure 3A and 3B), whereas the administration of mitoTEMPO or Pyr3 significantly suppressed the excessive vasoconstriction induced by either phenylephrine or U46619 in SHRs (Figure 3C and 3D). These findings suggested that increased TRPC3 activity at both the cytoplasmic and mitochondrial levels regulated Ca^{2+} homeostasis in the vasculature from SHRs. Inhibition of TRPC3 improved vascular tone in the setting of hypertension.

**Inhibition of TRPC3 Improved Mitochondrial Function and Reduced ROS Production in the Vasculature of SHRs**

We then investigated the effect of telmisartan and Pyr3 treatment on mitochondrial ROS production and respiratory functions in VSMCs. Specifically, parameters of mitochondrial respiratory function, such as CI_OXPHOS, CI+II_OXPHOS, and CI+II_ETS, were significantly reduced in the VSMCs from SHRs compared with those from WKY rats, whereas telmisartan treatment significantly improved these parameters (Figure 4A). Furthermore, increased cellular and mitochondrial ROS production, enhanced H_2O_2 production, but impaired ATP synthesis were identified in SHR compared with WKY. Both telmisartan and Pyr3 treatment significantly reversed these changes in mitochondrial parameters (Figure 4B through 4E). Specifically, the phosphorylation of the pyruvate dehydrogenase E1α subunit (phospho-PDHE1α) was significantly increased, but total PDHE1α was not changed in the VSMCs from SHRs compared with WKY rats. Both telmisartan and Pyr3 treatment significantly reduced the phospho-PDHE1α expression levels (Figure 4F). These results indicated that the inhibition of TRPC3 improved mitochondrial respiratory
function and reduced ROS production in the setting of hypertension.

**Chronic Telmisartan Treatment Attenuated the Vasoconstrictions Associated With the Inhibition of Mitochondrial TRPC3**

We further investigated the effect of TRPC3 inhibition on mitochondrial function and vascular tone in vivo. The total and mitochondrial TRPC3 expression levels were significantly increased in the aortas of SHRs compared with WKY rats, but both were attenuated by long-term telmisartan administration (Figure 5A, Figure S1). Moreover, chronic telmisartan treatment decreased cellular and mitochondrial ROS production in aortas of SHRs (Figure 5B). The enzyme activities of mitochondrial complex I, but not mitochondrial complex II, were significantly reduced in aortas of SHRs, and this decrease was attenuated by chronic telmisartan treatment (Figure 5C).

Chronic telmisartan treatment also significantly inhibited increases in vasoconstriction (Figure 5D) but only slightly improved endothelium-dependent relaxations and had no effect on endothelium-independent relaxations in SHRs (Figure S2A). Incubation with mitoTEMPO or Pyr3 only slightly improved the vascular constrictions in SHRs with

Figure 3. Mitochondria participate in calcium handling and vasoconstriction in the vasculature from WKY rats and SHRs. A and B, VSMCs from WKY rats and SHRs were pretreated with 10 μmol/L of the mitochondria-target reactive oxygen species (ROS) scavenger mitoTEMPO, 10 μmol/L of telmisartan or both for 24 hours, and 1 μmol/L of thapsigargin (TG) was then added to detect the store-operated calcium entry (SOCE). ***P<0.0001 vs WKY; **P<0.01 vs SHR control; #P<0.0001 vs SHR control. C and D, The effect of 50 μmol/L of mitoTEMPO and 10 μmol/L of the TRPC3 inhibitor Pyr3 incubation on U46619- and phenylephrine (PE)-induced vasoconstriction in mesenteric arteries from SHR, compared with WKY rats. N=6 to 8 per group. *P<0.05, **P<0.01, ***P<0.0001. Pyr3 indicates specific inhibitor of TRPC3; SHR, spontaneously hypertensive rats; Telmi, telmisartan; TRPC3, transient receptor potential channel, canonical type 3; VSMC, vascular smooth muscle cells; WKY, Wistar-Kyoto.
chronic telmisartan treatment, but without significant changes (Figure 5E). Furthermore, the administration of telmisartan consistently lowered blood pressure in SHRs (Figure S2B and S2C). Taken together, these results indicated that the inhibition of TRPC3 improved the vascular tone of SHRs both in vivo and in vitro.

TRPC3 Knockout Ameliorated Angiotensin II–Induced Mitochondrial ROS Production and Hypertension

Specifically, mitoTEMPO or Pyr3 administration significantly attenuated vasoconstriction induced by U46619 and PE in
wild-type mice (Figure 6A). Meanwhile, Trpc3−/− significantly attenuated the enhanced mitochondrial Ca2+ uptake induced by angiotensin II infusion (Figure 6B and 6C). The total and mitochondrial ROS production on angiotensin II infusion was also decreased in the vasculature of Trpc3−/− mice compared with wild-type mice (Figure 6D). Additionally, angiotensin II significantly increased the phosphorylation of PDHE1α with no effect on the total PDHE1α expression levels in the aorta of wild-type mice, but this increase was partially ameliorated in Trpc3−/− mice (Figure 6E).

Furthermore, we used in vivo experiments to validate the role of TRPC3 in angiotensin II–induced hypertension and vasoconstriction. It showed that the angiotensin II–induced elevated tail-cuff systolic blood pressure, the 24-hour ambulatory blood pressure, as well as U46619- and PE-induced vasoconstriction were significantly attenuated in Trpc3−/− mice (Figure 7A through 7C). Moreover, the activation of RhoA/Rho kinase due to angiotensin II infusion was also partially inhibited in Trpc3−/− mice, and this effect was mediated by the inhibition of MYPT1 and MLC2 phosphorylation (Figure 7D through 7F). These data indicate that TRPC3 may act by regulating mitochondrial functions, thus influencing the redox state and RhoA/Rho kinase pathway, which modulates vascular tone and blood pressure in hypertension.

### Discussion

This study is the first to provide important evidence showing that increased vascular mitochondrial TRPC3 function participates in abnormal mitochondrial Ca2+ homeostasis and enhances vascular tone in the setting of hypertension, and this regulation is associated with increased mitochondrial ROS production and impaired ATP synthesis. Moreover, long-term telmisartan administration improves mitochondrial function and decreases mitochondrial ROS production and vascular constriction by inhibiting mitochondrial TRPC3 in the vasculature from SHRs (Figure 8). Furthermore, a global knockout of TRPC3 attenuates angiotensin II–induced ROS production, suppresses vasoconstriction and lowers blood pressure in vivo. In our study, we demonstrated a novel mechanism by which enhanced mitochondrial TRPC3-mediated ROS production is involved in mitochondrial redox signaling and calcium dysregulation in the vasculature from a hypertensive model.

Mitochondrial Ca2+ is vital to mitochondrial function because it regulates the activities of Ca2+-sensitive enzymes in the Krebs cycle. The regulation of mitochondrial Ca2+ homeostasis is complicated, including a pro-uptake mitochondrial calcium uniporter, a prorelease sodium-calcium exchanger, a sodium-hydrogen exchanger, and a mitochondrial permeability transition pore. In this study, we provide evidence to show that elevated mitochondrial Ca2+ uptake is associated with enhanced mitochondrial Ca2+ uptake in hypertension and that telmisartan can decrease mitochondrial Ca2+ uptake by inhibiting TRPC3 in the vasculature from SHRs. Recently, Feng et al reported that 44% of total TRPC3 is localized to the inner membrane of mitochondria. We confirmed that mitochondrial TRPC3 expression was increased by 56% in the VSMCs from SHRs compared with WKY rats, whereas treatment with ATP enhanced the [Ca2+]m in the permeabilized VSMCs from SHRs compared with WKY rats. Inhibition of TRPC3 attenuated these elevated [Ca2+]m levels in the VSMCs from SHRs. Furthermore, TRPC3 overexpression enhanced [Ca2+]m in permeabilized VSMCs from WKY rats. Therefore, targeting mitochondrial TRPC3 may modulate the mitochondrial Ca2+ homeostasis in the vasculature of hypertensive individuals.

Mitochondrial ROS plays a role in the regulation of vascular tone by influencing the functions of VSMCs and the endothelium. A recent study shows that mitochondrial ion channels/transporters act as sensors and regulators of cellular redox signaling. Under physiological conditions, Ca2+ diminishes ROS from both complexes I and III while enhancing ROS generation if these complexes are dysfunctional. However,
excessive mitochondrial Ca\(^{2+}\) uptake promotes ROS production.\(^{36}\) In this study, we provide evidence showing that the elevated mitochondrial TRPC3-mediated Ca\(^{2+}\) uptake is associated with increased mitochondrial ROS production in SHR. Chronic telmisartan administration decreased mitochondrial ROS levels by 56% in the VSMCs and by 55% in the aortas of SHRs through inhibiting TRPC3 and improving the enzyme activities of complexes I and II in the mitochondrial respiratory chain. Generally, mitochondrial matrix Ca\(^{2+}\) can activate PDH at its E1\(_{a}\) subunit and promote the transformation of pyruvic acid to acetyl-CoA in the mitochondrial matrix.\(^{3}\) PDH is a key dehydrogenase, and its activity can also be blunted by...
Figure 6. The effects of TRPC3 on angiotensin II (Ang II)-induced vascular mitochondrial dysfunctions. A, The effects of Pyr3 and mitoTEMPO administration on vascular constrictions of MAs in Ang II-infused hypertensive mice. N = 6 to 8 per group. *P < 0.05, **P < 0.01, ***P < 0.0001. B and C, [Ca²⁺]mito changes in permeabilized primary VSMCs from WT and Trpc3⁻/⁻ mice, pretreated with 200 nmol/L Ang II and challenged with the cytosolic loading of 300 μmol/L (B) or 75 μmol/L (C) Ca²⁺. N = 9 per group. ***P < 0.0001. D, Representative images of DHE- and MitoSOX-stained aortic sections from Ang II-infused WT and Trpc3⁻/⁻ mice. N = 7 per group. ***P < 0.0001. E, Immunoblotting of the expression levels of TRPC3, p-PDHE1α and t-PDHE1α in aortic tissues isolated from WT and Trpc3⁻/⁻ mice, using GAPDH as a loading control. Four Western blot bands in each group were quantified and analyzed in the right panels. *P < 0.05, ***P < 0.0001. DHE indicates dihydroethidium; MA, mesenteric artery; MitoSOX, mitochondrial superoxide indicator; Pyr3, specific inhibitor of TRPC3; TRPC3, transient receptor potential channel, canonical type 3; VSMC, vascular smooth muscle cells; WT, wild type.
angiotensin II through increasing the vascular PDH phosphorylation.\textsuperscript{15} However, the regulation of PDH activities in the vasculature in hypertension is poorly understood. In this study, we demonstrated that the phosphorylation of PDHE1\(\alpha\) was significantly increased by 101%, but total PDHE1\(\alpha\) was not changed in the VSMCs from SHRs compared with WKY rats. Moreover, parameters of mitochondrial respiratory functions and the enzyme activity of mitochondrial Complex I were...
impaired in the vasculature from SHRs. Furthermore, mitochondrial TRPC3 inversely correlated with the activities of PDH in the vasculature of SHRs and angiotensin II–infused mice, which may be partially attributable to TRPC3-mediated vascular mitochondrial redox signaling and calcium dysregulation. PDHE1α phosphorylation is mediated by redox-sensitive PDH kinase, a kinase that could be activated by mitochondrial ROS.37,38 Therefore, reduction of mitochondrial ROS in the VSMCs from TRPC3−/− mice can be responsible for reduced PDH kinase activity and recovery of PDH activity, increased mitochondrial Complex I/oxphos levels, and ATP synthesis. Angiotensin II may exert AT1R-independent effect by targeting TRPC3 in the vasculature. Although the role of AT1R-NADPH oxidase by modulating the cellular and mitochondrial ROS productions in cardiovascular diseases has been investigated,19,39,40 recent studies have shown that TRPC3 participates in RAS-related cardiovascular complications.41 Angiotensin II–induced vasomotion was associated with increased TRPC3 expression in the mesenteric arteries from SHRs.42 TRPC3 is involved in atherosclerosis through regulation of vascular cell adhesion molecule-1 and phospho-IκBα expression in apoE−/− mice,43 and the inhibition of TRPC3 has been shown to reduce pathological cardiac hypertrophy.11,44 We recently showed that long-term taurine supplementation improved vascular tone by increasing plasma H2S content and targeting TRPC3-mediated Ca2+ influx in SHRs.12 Other groups reported that TRPC3 influenced contractility and peripheral vascular resistance in hypertension.45,46 In the present study, we provided experimental evidence that angiotensin II can regulate [Ca2+]mito, ROS production, and mitochondrial energy metabolism through targeting TRPC3. Specifically, the angiotensin II–induced activation of the RhoA/Rho kinase pathway was significantly attenuated in Trpc3−/− mice. We have shown that the expression levels of AT1R in the vasculatures of WKY rats and SHRs did not significantly differ,13 which was in agreement with other reports.47 There were studies that indicated that

Figure 8. A schematic illustration depicts the mechanism by which increased mitochondrial TRPC3 contributes to hypertension. SHR or Ang II–infusion hypertension have increased mitochondrial TRPC3 expression levels, which induced an enhanced mitochondrial Ca2+ uptake, impaired mitochondrial respiratory functions, and increased ROS production. These abnormalities lead to enhanced ROS production, increased [Ca2+]c, and activation of the RhoA/Rho kinase pathway in hypertension. Inhibition of TRPC3 by telmisartan or Pyr3 ameliorated mitochondrial Ca2+ overload, restored PDH activities, and improved mitochondrial respiratory functions. Targeting TRPC3 may become a new strategy to antagonizing hypertension. Ang indicates angiotensin; PDH, pyruvate dehydrogenase; Pyr3, specific inhibitor of TRPC3; ROS, reactive oxygen species; SHR, spontaneously hypertensive rats; TRPC3, transient receptor potential channel, canonical type 3; VSMC, vascular smooth muscle cells.
Enhanced Mitochondrial TRPC3 in Hypertension

Wang et al

mitochondrial angiotensin receptors existed in many other models.48,49 Therefore, we proposed that angiotensin II may exert an AT1R-independent effect by targeting TRPC3.

Telmisartan as a first line antihypertensive drug is commonly used clinically.22 We showed before that telmisartan improved the insulin resistance and body weight by activating peroxisome proliferator-activated receptor-δ,50,51 Telmisartan has been proven to promote phosphorylation of endothelial nitric oxide synthase and improve mitochondrial function in VSMCs in a peroxisome proliferator-activated receptor-γ-dependent manner.52,53 Moreover, a recent study showed that telmisartan modulates the balance between oxidative stress and antioxidant properties, which improves cardioprotection, but the mechanism is unclear.54 In this study, the long-term administration of telmisartan inhibited mitochondrial Ca2+ uptake, reduced ROS production, and improved vascular tone through inhibition of vascular mitochondrial TRPC3 in vivo. However, the effect of telmisartan in improving mitochondrial functions may attributed to several pathways, which include reduced NADPH oxidase activity,52 reduced inflammation,55,56 and diminished Ca2+-induced mitochondrial oxidative stress.

In summary, we tested the hypothesis that increased TRPC3-mediated mitochondrial Ca2+ uptake in VSMCs and aortic tissues of SHRs compared with WKY rats. TRPC3 knockout significantly reduced angiotensin II–induced ROS production and vasoconstriction. Telmisartan shows promise in the treatment of hypertension through inhibition of TRPC3 and improvement of vascular mitochondrial redox signaling and calcium dysregulation.

Study Limitations

The limitation of this study is that it cannot rule out the plasma membrane TRPC3 channel which also contributes to the regulation of calcium handling13 and ROS generation.57 Further experiments are needed to distinguish plasma membrane– and mitochondrial TRPC3–mediated effects. In addition, they should also examine how TRPC3 is integrated into mitochondria and whether this process is genetically altered in the vasculature of hypertensive rats.

Acknowledgments

We gratefully acknowledge the technical assistance of Tingbing Cao and Lijuang Wang (Chongqing Institute of Hypertension, Chongqing, China) with our experiments.

Sources of Funding

This study was funded by the National Natural Science Foundation of China (81370366), the National Basic Research Program of China (2013CB5311205), the National Natural Science Foundation of China (81600331), and the Natural Science Foundation of Chongqing (cstc2012jjA10123).

Disclosures

None.

References

1. Wang L, Yang X, Shen Y. Molecular mechanism of mitochondrial calcium uptake. Cell Mol Life Sci. 2015;72:1489–1498.
2. Gorlach A, Bertram K, Hudecova S, Krizanov O. Calcium and ROS: a mutual interplay. Redox Biol. 2015;5:260–271.
3. Cardenas C, Miller RA, Smith I, Bui T, Molgo J, Muller M, Vais H, Cheung KH, Yang J, Parker I, Thompson CB, Birmbaum MJ, Hallows KR, Foskett JK. Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell. 2010;142:270–283.
4. Estebregg R, Linbo T, Pickett SB, Wu P, Ou HC, Rubel EW, Raible DW. Mitochondrial calcium uptake underlies ROS generation during aminglycoside-induced heart cell death. J Clin Invest. 2016;126:3556–3566.
5. Williams GS, Boyman L, Chikando AC, Kairallah RJ, Lederer WJ. Mitochondrial calcium uptake. Proc Natl Acad Sci USA. 2013;110:10479–10486.
6. Chiong M, Cartes-Saavedra B, Norrambuena-Soto I, Mondaca-Ruff D, Morales PE, Garcia-Miguel M, Melloado R. Mitochondrial metabolism and the control of vascular smooth muscle cell proliferation. Front Cell Dev Biol. 2014;2:72.
7. Liu MY, Jin J, Li SL, Yan J, Zhen CL, Gao JL, Zhang YH, Zhang YQ, Shen X, Zhang LS, Wei YI, Zhao Y, Wang CG, Bai YL, Dong DL. Mitochondrial fission of smooth muscle cells is involved in artery constriction. Hypertension. 2016;68:1245–1254.
8. Dikovsi SI, Ungvari Z. Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol. 2013;305:H1417–H1427.
9. Trebak M, Ginnan R, Singer HA, Jourdeheul D. Interplay between calcium and reactive oxygen/nitrogen species: an essential paradigm for vascular smooth muscle signaling. Antioxid Redox Signal. 2010;12:657–674.
10. Yang D, Luo Z, Ma S, Wong WT, Ma L, Zhong J, He H, Zhao Z, Cao T, Yan Z, Liu D, Arendshorst WJ, Huang Y, Tepel M, Zhu Z. Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension. Cell Metab. 2010;12:130–141.
11. Sun J, Yang T, Wang P, Ma S, Zhu Z, Pu Y, Li L, Zhao Y, Xiong S, Liu D. Activation of cold-sensing transient receptor potential melastatin subtype 8 antagonizes vasoconstriction and hypertension through attenuating RhoA/Rho kinase pathway. Hypertension. 2014;63:1354–1363.
12. Sun Q, Yang W, Li Y, Sun F, Li P, Xia W, Zhou X, Li Q, Wang X, Chen J, Zeng X, Zhao Z, He H, Liu D, Zhu Z. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo-controlled study. Hypertension. 2016;67:541–549.
13. Liu D, Yang D, He H, Chen X, Cao T, Feng X, Ma L, Luo Z, Wang L, Yan Z, Zhu Z, Tepel M. Increased transient receptor potential canonical type 3 channels in vasculature from hypertensive rats. Hypertension. 2009;53:70–76.
14. Feng S, Li H, Tai Y, Huang J, Su Y, Abramovitz J, Zhu MX, Birnbaum L, Wang Y. Canonical transient receptor potential 3 channels regulate mitochondrial calcium uptake. Proc Natl Acad Sci USA. 2013;110:11011–11016.
15. Calderon-Cortes E, Cortes-Rojo C, Clemente-Guerrero M, Manzo-Avalos S, Villalobos-Molina R, Boldogh I, Saavedra-Molina A. Changes in mitochondrial functionality and calcium uptake in hypertensive rats as a function of age. Mitochondrion. 2008;8:262–272.
16. Pardo AC, Rinaldi GJ, Mosca SM. Mitochondrial calcium handling in normotensive and spontaneously hypertensive rats: correlation with systolic blood pressure levels. Mitochondrion. 2015;20:75–81.
17. Yamamoto S, Shimizu S, Kiyonaka S, Takahashi N, Wajima T, Hara Y, Negoro T, Yang J, Parker I, Thompson CB, Birnbaum MJ, Hallows KR, Foskett JK. Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell. 2010;142:270–283.
18. Ding Y, Winters A, Ding M, Graham S, Akopova I, Muallim S, Wang Y, Hong JH, Greczynski Z, Yang SH, Birnbaumer L, Ma R. Reactive oxygen species-mediated TRPC6 protein activation in vascular myocytes, a mechanism for vasoconstrictor-regulated vascular tone. J Biol Chem. 2011;286:31799–31809.
Enhanced Mitochondrial TRPC3 in Hypertension  Wang et al

19. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res. 2010;107:106–116.

20. Karpova T, Danchuk S, Kolobova E, Popov KM. Characterization of the isoforms of pyruvate dehydrogenase phosphatase: implications for the regulation of pyruvate dehydrogenase activity. Biochim Biophys Acta. 2003;1652:126–135.

21. Mori J, Arobo DA, Waggs CS, Harris RA, Lopaschuk GD, Oudit GY. ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol. 2013;304:H1103–H1113.

22. Sueta D, Koibuchi N, Hasegawa Y, Toyama K, Uekawa K, Katayama T, Ma M, Tsuchiya T, Kataoka K, Fujita Y, Hasegawa T, Nakagawa H, Nishina H, Kohara T, Morita S, Matsuzawa Y, Kaji T, Sumimoto H, Amano S, Watanabe T, Okada M, Yamasaki T, Okada Y, Fujita K, Nakao K, Okada H, Matsubara Y, Hori H, Kato H, Takano S, Kajimura S. The Bcl-2/xL inhibitor ABT-199 enhances the antihypertensive effects of sodium 1 type 3 channels: their role in hypertrophy and its related complications. J Cardiovasc Pharmacol. 2013;61:455–460.

23. Chen X, Yang D, Ma S, He H, Luo Z, Feng X, Cao T, Ma L, Yan Z, Liu D, Tepel M, Zhu Z. Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels. J Cell Mol Med. 2010;14:2483–2494.

24. Smedlund KB, Birnbaumer L, Vazquez G. Increased size and cellularity of advanced atherosclerotic lesions in mice with endothelial overexpression of the human TRPC3 channel. Proc Natl Acad Sci USA. 2015;112:E2201–E2206.

25. Cook JL, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin II channel expression and vasomotor response in the aorta with age in both Wistar-Kyoto and spontaneously hypertensive rats. PLoS One. 2014;9:e88975.

26. Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, Carey RM, O’Rourke B, Walsnt JD. Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci USA. 2011;108:14849–14854.

27. Martinez-Revelles S, Avendano MS, Garcia-Redondo AB, Alvarez Y, Aguado A, Perez-Giron JV, Garcia-Redondo L, Esteban V, Redondo JM, Alonso MJ, Briones AM. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal. 2013;18:65–165.

28. Martinez-Revelles S, Avendano MS, Garcia-Redondo AB, Alvarez Y, Aguado A, Perez-Giron JV, Garcia-Redondo L, Esteban V, Redondo JM, Alonso MJ, Briones AM. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal. 2013;18:65–165.

29. Amaral JM, Menonengro MF, Pinheiro LC, Ferreira GG, Barroso RP, Costa-Filho AJ, Tanus-Santos JE. TEMPOL enhances the antihypertensive effects of sodium nitrite by mechanisms facilitating nitrite-derived gastric nitric oxide formation. Free Radic Biol Med. 2013;65:446–455.

30. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS. Calcium, ATP, and mitochondria-associated membranes and mitochondria from animal tissues and cells. Nat Protoc. 2009;4:1582–1590.

31. Liu L, Liu I, Wong WT, Tian YX, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidylpeptide 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012;60:833–841.

32. O-Uchii J, Ryu SY, Ijhan BS, Hurst S, Sheu SS. Mitochondrial ion channels/transporters as sensors and regulators of cellular redox signalling. Antioxid Redox Signal. 2014;21:987–1006.

33. Itani HA, Dikalova AE, McMaster WG, Nazarewicz RR, Bikineyeva AT, Harrison DG, Dikalov SI. Mitochondrial cyclophilin D in vascular oxidative stress and hypertension. Hypertension. 2016;67:128–1327.

34. Martinez-Revelles S, Avendano MS, Garcia-Redondo AB, Alvarez Y, Aguado A, Perez-Giron JV, Garcia-Redondo L, Esteban V, Redondo JM, Alonso MJ, Briones AM. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal. 2013;18:51–65.

35. Aldaakak M, Stowe DF, Dash RK, Camara AK. Mitochondrial handling of excess Ca2+ is substrate-dependent with implications for reactive oxygen species generation. Free Radic Biol Med. 2013;64:195–203.

36. Wu CA, Chao Y, Shiah SG, Lin WW. Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase. Biochim Biophys Acta. 2013;1833:1147–1156.

37. Kiriti K, Hu Y, Komatsu N. HIF-1 prevents the overproduction of mitochondrial ROS after cytokine stimulation through induction of PDK-1. Cell Cycle. 2009;8:2844–2849.

38. Dikalova SI, Nazarewicz RR, Bikineyeva A, Hilenski L, Lassaguet B, Griendling KK, Harrison DG, Dikalov AE. Nox2-induced production of mitochondrial superoxide in angiotensin II-mediated endothelial oxidative stress and hypertension. Antioxid Redox Signal. 2014;20:281–294.

39. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med. 2011;51:1298–1301.

40. Wang P, Liu D, Tepel M, Zhu Z. Transient receptor potential canonical type 3 channels—their role in hypertrophy and its related complications. J Cardiovasc Pharmacol. 2013;61:455–460.

41. Seo K, Rainer PP, Shaldy Hahn V, Lee DI, Jo SH, Anderson A, Liu T, Xu X, Willette RN, Lepore JP, Marinino JP, Birnbaumer L, Schnackenberg CG, Kass DS. Enhanced TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. Proc Natl Acad Sci USA. 2014;111:1551–1556.

42. Chen X, Yang D, Ma S, He H, Luo Z, Feng X, Cao T, Ma L, Yan Z, Liu D, Tepel M, Zhu Z. Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels. J Cell Mol Med. 2010;14:2483–2494.

43. Cook JL, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res. 2001;89:1138–1146.

44. He H, Yang D, Ma L, Luo Z, Ma S, Feng X, Cao T, Yan Z, Liu D, Tepel M, Zhu Z. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-δ-dependent pathways. Hypertension. 2010;56:846–859.

45. Li L, Luo Z, Yu H, Feng X, Wang P, Chen J, Pu Y, Zhao Y, He H, Zhong J, Liu D, Zhu Z. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation. Diabetes. 2013;62:762–774.

46. Wenzel P, Schulz E, Oelze M, Muller J, Schaham S, Alhamdani MS, Debrezion J, Hortmann M, Reifenberg K, Fleming I, Munzel T, Daiber A. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med. 2008;45:619–626.

47. Takeuchi K, Yamamoto K, Oishi M, Takeshita H, Hongyo K, Kawai T, Takeda M, Kamide K, Kurz T, Rakugi H. Telmisartan modulates mitochondrial function in vascular smooth muscle cells. Hypertens Res. 2013;36:433–439.

48. Yoo SM, Choi SH, Jung MD, Lim SC, Baek SH. Short-term use of telmisartan attenuates oxidation and improves Prx2 expression more than antioxidant β-blockers in the cardiovascular systems of spontaneously hypertensive rats. Hypertens Res. 2015;38:106–115.

49. Pang T, Wang J, Benicky J, Sanchez-Lemus E, Saavedra JM. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways. J Neuroinflammation. 2012;9:102.

50. Toba H, Tojo C, Wang J, Noda K, Kobara M, Nakata T. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rats. Eur J Pharmacol. 2012;685:91–98.

51. Kitajima N, Numaga-Tomita T, Watanabe M, Kuroda T, Nishimura A, Miyano K, Yasuda S, Kuwahara K, Sato Y, Ide T, Birnbaumer L, Sumimoto H, Mori Y, Nishida M. TRPC3 positively regulates reactive oxygen species driving maladaptive cardiac remodeling. Sci Rep. 2016;6:37001.
SUPPLEMENTAL MATERIAL
Figure S1.

A

|       | TRPC3 | α-actin | DAPI | Merge |
|-------|-------|---------|------|-------|
| WKY-ND| ![Image](image1) | ![Image](image2) | ![Image](image3) | ![Image](image4) |
| SHR-ND| ![Image](image5) | ![Image](image6) | ![Image](image7) | ![Image](image8) |
| SHR-Telmi| ![Image](image9) | ![Image](image10) | ![Image](image11) | ![Image](image12) |

Relative Immunofluorescence Intensity (TRPC3)

WKY | SHR
ND | ND | Telmi

Relative Immunofluorescence Intensity (α-actin)

WKY | SHR
ND | ND | Telmi

B

Aortic Tissue

|       | TRPC3 | GAPDH |
|-------|-------|-------|
| WKY-ND| ![Image](image13) | ![Image](image14) |
| SHR-ND| ![Image](image15) | ![Image](image16) |
| SHR-Telmi| ![Image](image17) | ![Image](image18) |

Relative Expression Levels (TRPC3/GAPDH)

WKY | SHR
ND | ND | Telmi

*** | ** |
Figure S2

A

B

C
Supplemental Figure Legends:

**Figure S1.** The effect of chronic telmisartan treatment on TRPC3 expression levels. 
A, Representative images of the immunofluorescence staining of TRPC3, α-smooth actin and DAPI using aortic sections from WKY rats and SHRs, subjected to or forgoing telmisartan intervention. Quantification of the intensities in each graph was presented in the right panel. N=6 per group. *P<0.05, ***P<0.0001. B, Expression levels of TRPC3 in aortic tissues from these groups were detected using western blot. Quantification of western blot bands was presented as the amount of target protein / GAPDH levels. N=4 per group. **P<0.01, ***P<0.0001.

**Figure S2.** The effect of chronic oral telmisartan intervention on blood pressure (BP) levels in SHRs. A, Effects of telmisartan treatment on acetylcholine (ACH)- and nitroglycerin-induced relaxation in mesenteric arteries (MAs) from WKY rats and SHRs. N=8~12 per group. Concentration-response curves were analyzed by non-linear regression followed by Student’s t-test or one-way ANOVA for comparisons between two groups or among more than two groups, respectively. *P<0.05 vs 10^{-7}mol/L Ach-induced relaxation of SHR MAs; ***P<0.0001 vs SHR. B, Effects of 12-week telmisartan intervention on the tail-cuff systolic blood pressure (SBP) levels of SHR. N=10 per group. ***P<0.0001 vs WKY at baseline, #P<0.0001 vs SHR-Telmi at baseline using repeated measures ANOVA, †P<0.0001 vs SHR at the same time point. C, Effects of telmisartan intervention on the 24-hour ambulatory BP levels in SHRs. N=5 per group. **P<0.01, ***P<0.0001.